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Endocytic downregulation is a pivotal mechanism
turning off signalling from the EGF receptor (EGFR). It
is well established that whereas EGF binding leads to
lysosomal degradation of EGFR, transforming growth
factor (TGF)-α causes receptor recycling. TGF-α therefore
leads to continuous signalling and is a more potent
mitogen than EGF. In addition to EGF and TGF-α,ﬁ v e
EGFR ligands have been identiﬁed. Although many of
these ligands are upregulated in cancers, very little is
known about their effect on EGFR trafﬁcking.
We have compared the effect of six different ligands on
endocytic trafﬁcking of EGFR. We ﬁnd that, whereas
they all stimulate receptor internalization, they have
very diverse effects on endocytic sorting. Heparin-
binding EGF-like growth factor and Betacellulin target
all EGFRs for lysosomal degradation. In contrast, TGF-
α and epiregulin lead to complete receptor recycling.
EGF leads to lysosomal degradation of the majority
but not all EGFRs. Amphiregulin does not target EGFR
for lysosomal degradation but causes fast as well
as slow EGFR recycling. The Cbl ubiquitin ligases,
especially c-Cbl, are responsible for EGFR ubiquitination
after stimulation with all ligands, and persistent EGFR
phosphorylation and ubiquitination largely correlate
with receptor degradation.
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The epidermal growth factor receptor (EGFR) is a receptor
tyrosine kinase involved in normal cellular growth and
differentiation as well as in the pathogenesis of cancer.
Seven different EGFR ligands have been identiﬁed: EGF,
transforming growth factor-α (TGF-α), heparin-binding
EGF-like growth factor (HB-EGF), betacellulin (BTC),
amphiregulin (AR), epiregulin (EPI), and epigen (1). Several
of the ligands are found in increased concentrations in
human cancers, where they engage in auto- and paracrine
signalling stimulating tumour progression (2–4).
Endocytic sorting is an important mechanism regulating
EGFR signalling. Upon ligand-binding, EGFR is internalized
and trafﬁcked to endosomes. From endosomes, the
receptor is either recycled to the cell surface, or it
is transported to lysosomes for degradation (recently
reviewed in (5)). The sorting to lysosomes is regulated
by ubiquitination of the receptor, which in turn is
dependent on the pH sensitivity of the ligand-binding.
The EGF binding to EGFR is relatively stable at the
pH of endosomes, so upon EGF binding EGFR is
continuously ubiquitinated by the Cbl ubiquitin ligases (6)
and transported to lysosomes (7,8). In contrast, TGF-α
rapidly dissociates from the receptor when exposed to
the low pH of endosomes (9), and the receptor becomes
de-ubiquitinated and is therefore recycled back to the
plasma membrane (7,10).
Whether EGFR is degraded in lysosomes or recycled to
the plasma membrane is vital for the duration of the
EGFR signal. Following receptor degradation, the EGFR
signal will be diminished until the number of EGFRs at
the plasma membrane has been reestablished by protein
synthesis. In contrast, following receptor recycling, the
cell is immediately able to undergo an additional round of
full EGFR activation. In accordance with this, TGF-α is a
more potent mitogen than EGF (11). At present, very little
is known about how the remaining EGFR ligands affect
endocytic sorting and degradation of EGFR, although
several studies have shown that they differ substantially
in their oncogenic potential (3,4,12,13).
In this study we have compared the effects of six different
EGFR ligands on EGFR endocytosis, phosphorylation,
ubiquitination,degradation,andrecycling.Alloftheligands
stimulate EGFR endocytosis. However, their effects on
intracellular trafﬁcking of EGFR vary signiﬁcantly, from
complete recycling to complete lysosomal degradation.
Whether EGFR is recycled or degraded after stimulation
with the various ligands correlates well with persistent
receptor phosphorylation and also with persistent Cbl
ubiquitin ligase-dependent receptor ubiquitination and pH
sensitivity of ligand-binding.
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Based on our results and the current knowledge about the
role of EGFR ligands in the pathogenesis of cancer, we
propose that the oncogenic potential of the various EGFR
ligands in part depends on their ability to induce receptor
recycling rather than degradation.
Results
EGFR ligands differentially induce receptor
internalization and recycling
To compare the ability of the different EGFR ligands to
induce internalization of EGFR, we used the common
approach of pre-binding ligand on ice, thereby looking at
a synchronized wave of receptor internalization (7,14,15).
We initially determined the incubation time necessary
to obtain maximal ligand-binding. First,125I-EGF binding
to HEp2 cells as a function of time was tested, and
in Figure S1A it is seen that the equilibrium is reached
after only 15 min. To investigate the binding kinetics of
the other ligands to EGFR, cells were incubated with
unlabelledligandoniceforupto2 h.Thereafter,cellswere
brieﬂy washed followed by binding of 125I-EGF for 30 min.
The level of 125I-EGF binding reﬂects unbound EGFRs.
In Figure S1B it is seen that all ligands have reached
maximal binding well before 1 h. Thus, to investigate
EGFR internalization, HEp2 cells were incubated with
increasing ligand concentrations on ice for 1 h followed
by washing and 15 min chase at 37
◦C. Subsequently,
the amount of EGFR present at the cell surface was
determined by ﬂuorescence-activated cell sorter (FACS)
analysis.AsseeninFigure 1A,allsixligandsinducedEGFR
internalization. However, the degree of internalization
varied between the ligands. HB-EGF and BTC were very
efﬁcient at inducing EGFR internalization. At saturating
concentrations of ligand, 70–80% of cell surface EGFR
was internalized upon the 15 min chase. EGF and TGF-α
both induced internalization of approximately 50% of the
receptors at saturating concentrations of ligand. In case
of EPI and AR, the internalization did not reach saturation
with the ligand concentrations used. This is in accordance
with the fact that these two ligands have a lower afﬁnity
for EGFR compared with the other ligands (16,17).
The varying capability of the ligands to clear EGFR from
the cell surface during a 15 min chase could be because
of different trafﬁcking properties. If a ligand induces a
substantial amount of EGFR recycling to the cell surface,
Figure 1: EGFR ligands differentially
affect EGFR endocytosis and recycling.
A) EGFR internalization following stimulation
with increasing concentrations of various
EGFR ligands. HEp2 cells were incubated on
ice with increasing concentrations of ligand
for 1 h, washed, and incubated at 37
◦Cf o r
15 min. Subsequently, the amount of EGFR
at the cell surface was determined by FACS
analysis. Data points represent mean +/−
SEM for three independent experiments.
B) Time–course of EGFR internalization and
recycling following stimulation with different
EGFR ligands. Cells were incubated on ice
with 10 or 100 nM of ligands as indicated,
washed, and incubated at 37
◦C for different
time periods. The amount of EGFR present
at the cell surface was determined by FACS
analysis. Data points represent mean +/−
SEM for four independent experiments.
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it will clear the cell surface for EGFR less efﬁciently
than a ligand that does not induce receptor recycling.
Such recycling can best be detected with pulse-chase
experiments, because continuous incubation with ligand
will cause recycled receptors to repeatedly undergo
endocytosis (Figure S2). Thus, to investigate recycling,
HEp2 cells were incubated with a ﬁxed concentration of
ligand on ice for 1 h, washed, and subsequently chased for
the indicated period of time (Figure 1B). At the end of the
chase, the amount of cell surface EGFR was quantiﬁed by
FACS analysis. In case of EGF, TGF-α, HB-EGF, and BTC,
10 nM of ligand was used because this concentration
induced a close to maximal EGFR internalization in the
experiment shown in Figure 1A. For the lower afﬁnity
ligands EPI and AR, a concentration of 100 nM was
used. Although the in vivo ligand concentrations have
not been determined for all of the investigated ligands,
it is conceivable that the concentrations used here
are physiologically and pathophysiologically relevant (see
discussion).
Ascanbeseenfrom Figure 1B, verylittleEGFRis recycled
to the cell surface following stimulation with HB-EGF
or BTC. In contrast, close to 100% of the receptors
is recycled following stimulation with either TGF-α or
EPI. EGF and AR give intermediary responses, and
induce recycling of approximately 50% of the internalized
receptors. Thus, the six EGFR ligands have very different
effects on EGFR trafﬁcking.
All ligands induce EGFR transport to EEA1-positive
endosomes
It is known that EGFR is transported through EEA1
positive endosomes after stimulation with EGF (18). To
furthertest trafﬁckingandintracellularlocalization ofEGFR
after stimulation with the other ligands, we investigated
the association of EGFR with EEA1 positive endosomes.
Cells were incubated with ligand on ice for 1 h, washed,
and incubated at 37
◦C for different time periods. They
were subsequently ﬁxed and labelled for EGFR and EEA1.
Figure 2A shows images of EGFR and EEA1 following
15 min of internalization. As can be seen, all six EGFR
ligands target EGFR to early EEA1-positive endosomes.
Figure 2B shows image quantiﬁcation of the amount of
cellular EGFR associated with EEA1 positive endosomes
at different time-points. All of the tested EGFR ligands
induce colocalization of EGFR with EEA1, peaking after
15–30 min of internalization. However, AR is slightly less
efﬁcient at targeting EGFR to EEA1-positive endosomes
than the other ligands.
EGFR ligands vary in their potential to stimulate
EGFR degradation
To test how the various EGFR ligands affect receptor
degradation, two different methods were applied. Cells
were stimulated with ligand for 1 h on ice, washed, and
chased for 0–8 h in the presence of cycloheximide to
inhibit de novo EGFR synthesis. The cells were subse-
quently lysed, and the amount of EGFR determined by
ELISA (Figure S3). Alternatively, to avoid the use of cyclo-
heximide, cells were pulse-labelled with 35S-methionine,
stimulated with ligand for 1 h on ice, washed, and incu-
b a t e df o r2o r6 ha t3 7
◦C. EGFR was subsequently
immunoprecipitated and the amount of 35S-labelled EGFR
quantiﬁed by PhosphorImaging of an SDS-PAGE gel
(Figure 3). As can be seen, stimulation with TGF-α, EPI,
or AR does not lead to signiﬁcant degradation of EGFR.
Stimulation with either EGF or HB-EGF leads to degrada-
tion of 40–60% of the cellular EGFR, whereas stimulation
with BTC leads to degradation of approximately 70% of
the cellular EGFR.
The degradation data following stimulation with EPI,
TGF-α, EGF, and BTC all correlate well with the degree of
EGFR recyclinginduced bytheligands (compareFigure 1B
and Figure 3). Interestingly, stimulation with AR does not
lead to signiﬁcant degradation for up to 6 h of EGFR in
spite of the fact that only half of the internalized receptors
are recycled within the time of the recycling experiment.
One possible explanation for this is that EGFR is recycled
more slowly after stimulation with AR compared with
other ligands. To investigate this, we incubated cells with
eitherEGF orARfor1 honice,washed,andchasedfor6 h
at 37
◦C, 3 h longer than the recycling experiments shown
in Figure 1B. We subsequently measured the amount of
EGFR present at the cell surface by FACS analysis. Six
hours after EGF stimulation, 60% of the initial amount of
EGFR was present at the cell surface whereas 6 h after
AR stimulation, the amount of EGFR on the cell surface
was 80% of the initial level. This indicates that there may
be some additional, slow recycling after stimulation with
AR compared with EGF.
EGFR ligands differentially induce transport of EGFR
to Lamp1-positive endosomes
We next investigated which ligands that target EGFR
to lysosomes. Cells were incubated with ligand on ice
for 1 h, washed, and further incubated at 37
◦Cf o r
different time periods. They were subsequently ﬁxed
and labelled for EGFR and Lamp1, and imaged by
confocal microscopy. As can be seen from Figure 4A,
after 60 min of stimulation with TGF-α or EPI a
substantial amount of EGFR is present at the cell surface,
which correlates well with the lack of degradation and
complete recycling seen after stimulation with these
ligands. Stimulation with HB-EGF, BTC, or EGF for
60 min results in some colocalization of EGFR with
lysosomes. However, because the receptor is rapidly
degraded once it has reached lysosomes, it is difﬁcult
to quantify the amount of EGFR trafﬁcked to lysosomes.
Indeed, when lysosomal function was inhibited by
baﬁlomycin, mostEGFR could be found in lysosomesafter
120 min of stimulation with HB-EGF or BTC (not shown
and Figure 4B). Following 60 min of AR stimulation, a
substantial amount of EGFR appears to be located to
non-lysosomal vesicles (Figure 4A). Taking into account
the relatively lower colocalization with EEA1-positive
compartments (Figure 2B) and the slow recycling of
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Figure 2: EGFR localization to early endosomes following ligand stimulation. HEp2 cells were incubated on ice with 10 nM (EGF,
TGF-α, HB-EGF, and BTC) or 100 nM (AR and EPI) of ligand, washed, and incubated at 37
◦C for different time periods. Cells were ﬁxed
and labelled for EGFR and the early endosome marker EEA1. (A) shows confocal microscopy images of representative cells after 15 min
of EGFR internalization. The lower right panel shows a magniﬁed ﬁeld of the area boxed in the panel to the left. Bars, 10 μm. (B) shows
a quantiﬁcation of the amount of EGFR colocalizing with EEA1 in an average of 50–58 cells for each time-point +/− SEM.
EGFR after AR stimulation (see above), these data
indicate that AR leads to sorting of a small fraction of
EGFR to an intracellular compartment which is distinct
from EEA1- and Lamp-1-positive compartments and from
which EGFR slowly recycles. To further characterize this
compartment, we investigated colocalization of EGFR
with Rab-4 and Rab-11, which are markers of recycling
endosomes (19). Following 60 min of AR stimulation,
EGFR partially colocalizes with both Rab-4 and Rab-11
(Figure S4). This is in agreement with a recent paper
showing colocalization between EGFR and Rab-11 after
AR stimulation (20).
Based on the above results, it is clear that the different
EGFR ligands lead to very different trafﬁcking and down-
regulation of EGFR. We therefore further investigated the
molecular mechanisms underlying these differences.
AR, HB-EGF, and BTC bind to EGFR even at very
low pH
It is generally acceptedthat TGF-α leads to EGFR recycling
because the ligand dissociates from the receptor in the
acidic environment in endosomes. In contrast, EGF bind-
ingtoEGFRismoreresistanttolowpHandthusEGFleads
to degradation of the receptor (9). To investigate whether
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Figure 3: EGFR ligands differentially stimulate EGFR
degradation. Cells were incubated with 35S-methionine/cysteine
for 1–2 h followed by unlabelled medium for 3 h. The cells were
subsequently incubated on ice with 10 nM (EGF, TGF-α,H B - E G F ,
andBTC)or100nM(ARandEPI)ofligand,washed,andincubated
at 37
◦C for 2 or 6 h. Cells were lysed, immunoprecipitated EGFR
was separated by gel electrophoresis (upper image), and the
amount of radioactive EGFR was quantiﬁed by PhosphorImager.
The column bar graph shows mean +/− SEM for quantiﬁcation
of four independent experiments. Statistical difference from the
0 h control as determined by Student’s t-test is indicated by stars
(*: p < 0.05; ** p < 0.01).
there is a general correlation between receptor recy-
cling/degradation and pH dependence of ligand-binding,
cells were incubated with ligand on ice for 4 h and then
brieﬂy washed with buffers of varying pH followed by
binding of 125I-EGF. The amount of 125I-EGF bound to the
cells reﬂects the number of EGFRs from which ligand
has been removed during the acid wash (Figure 5). As
expected, TGF-α dissociates from the receptor at pH 6.5,
whereas EGF dissociates at a slightly lower pH 5.5 (9).
AR, BTC, and HB-EGF are highly acid-resistant and remain
bound to the receptor at physiologically relevant pH val-
ues. It was not possible to measure the pH dependence
of EPI because of the low afﬁnity of the ligand. The data
show that for EGF, TGF-α, HB-EGF, and BTC the pH sen-
sitivity of ligand-binding correlates well with the level of
receptor recycling/degradation. Surprisingly, AR binding
showed high acid resistance despite the fact that this lig-
and induces recycling and negligible degradation of EGFR.
EGFR ubiquitination largely correlates with receptor
degradation
Ubiquitination of the EGFR has been shown to target
the receptor for lysosomal degradation (7). We therefore
investigated to what degree the different EGFR ligands
induce EGFR ubiquitination. Cells were incubated with
ligand on ice for 1 h, washed, and chased for 5 min
at 37
◦C. Subsequently, EGFR was immunoprecipitated
and ubiquitination detected by western blotting. As can
be seen in Figure 6A, all ligands induce ubiquitination of
EGFR,albeit toavaryingextent.Toinvestigatethekinetics
of EGFR ubiquitination, cells were chased for 0 to 20 min
at 37
◦C. In Figure S5 it is seen that all ligands induce
85–100% of maximal ubiquitination after 5 min. After
this time-point, ubiquitination persists to different degrees
dependingontheligand.HB-EGFandinparticularBTCgive
strong and/or persistent EGFR ubiquitination. In contrast,
TGFα and EPI give low ubiquitination that is quickly
lost. AR gives a strong initial EGFR ubiquitination which,
however, is quickly lost. Compared with the ubiquitination
seen after HB-EGF and BTC, the level of EGF-stimulated
EGFR ubiquitination is low, but it is more persistent than
seen after TGFα, AR and EPI (Figure 6A and Figure S5).
After 60 min, the level of EGFR ubiquitination was back to
background levels for all ligands (data not shown). When
correlating the level and kinetics of EGFR ubiquitination
(Figures 6A and S5) with that of receptor degradation, it
is seen that the overall pattern of ubiquitination correlates
well with the ability of the various ligands to target EGFR
to lysosomal degradation.
AR does not stimulate persistent recruitment of c-Cbl
to EGFR
c-Cbl is an important ubiquitin ligase responsible for
ubiquitination of EGFR (21). It can bind to EGFR either
directly via phosphorylated Tyr1045 or indirectly via
Grb2 (22–24). To investigate how the different EGFR
ligands affect recruitment of c-Cbl to activated EGFR,
cells were incubated with ligand on ice for 1 h,
washed, and chased at 37
◦C for 0–15 min. Cells
were lysed in co-immunoprecipitation (IP) buffer, EGFR
immunoprecipitated, and the immunoprecipitate analysed
by western blotting for EGFR, c-Cbl, and Grb2. As can be
seen from Figure 6B,C, all ligands stimulate c-Cbl binding
to EGFR, but the association is more prolonged after
EGF and BTC stimulation than the remaining ligands. In
particular, AR stimulates a transient c-Cbl binding to EGFR
(Figure 6B). Based on the high ubiquitination level seen
after HB-EGF, it is surprising that we found a low c-Cbl
binding to EGFR after this ligand (see discussion). Like
c-Cbl, Grb2 bound EGFR more efﬁciently following EGF
or BTC stimulation for 15 min compared with the other
EGFR ligands (Figure 6C). This ﬁts well with the reports
that c-Cbl primarily binds EGFR via Grb2 (25).
Recruitment of c-Cbl to the EGFR and ubiquitination of
the receptor does not correlate after stimulation with
AR and HB-EGF, and this could indicate that c-Cbl is not
decisive for the ubiquitination of EGFR after stimulation
with all ligands.
Cbl ubiquitin ligases are important for EGFR
ubiquitination after stimulation with all ligands
tested
To further investigate the role of Cbl ubiquitin ligases
in EGFR ubiquitination, we transfected cells with small
interfering RNA (siRNA) against c-Cbl and/or Cbl-b,
another ubiquitin ligase reported to ubiquitinate EGFR
after EGF stimulation (26), and tested how this affected
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Figure 4: EGFR localization to lysosomes following ligand stimulation. A) HEp2 cells were incubated on ice with 10 nM (EGF,
TGF-α, HB-EGF, and BTC) or 100 nM (AR and EPI) of ligand, washed, and incubated at 37
◦C for 60 min. Cells were ﬁxed and labelled
for EGFR and the lysosomal marker Lamp1. Representative confocal microscopy images are shown. Note that in the case of TGF-α and
EPI, relatively little EGFR is found inside the cell, whereas EGFR is distinct at the plasma membrane (arrow heads). The lower panel
shows a magniﬁed ﬁeld of the areas boxed in the panels above. Arrows show colocalization. Bars, 10 μm. B) HEp2 cells were incubated
on ice with 10 nM BTC, washed, and incubated at 37
◦C in the presence of 500 nM baﬁlomycin A1 for 120 min. Cells were ﬁxed and
labelled for EGFR and Lamp1. Note that baﬁlomycin A1 induces an up-concentration of EGFR in lysosomes following BTC stimulation.
ubiquitination of EGFR after stimulation with the various
ligands. As seen in Figure 7, EGFR ubiquitination is partly
dependent upon c-Cbl for all the investigated ligands.
Knock down of Cbl-b alone does not diminish EGFR
ubiquitination, but double knock down of both ubiquitin
ligases does in some cases inhibit ubiquitination slightly
more efﬁciently than c-Cbl knock down alone. This shows
that Cbl ubiquitin ligases, in particular c-Cbl, are involved
in EGFR ubiquitination after stimulation with all ligands.
EGFR phosphorylation correlates with receptor
degradation
We next investigated phosphorylation of EGFR following
ligand stimulation. Whole-cell lysates from cells incubated
with ligand on ice for 1 h and subsequently chased at
37
◦C for 0–20 min were analysed by western blotting
using antibodies recognizing the major phospho-tyrosine
residue Tyr1173. As seen from Figure 8 all ligands
stimulate EGFR phosphorylation, but EGF, BTC, and
HB-EGF are more efﬁcient at stimulating persistent
EGFR phosphorylation. A similar pattern of Tyr1045,
Tyr1068 and Tyr1173 phosphorylation was seen when
cells were stimulated with ligand for 5 or 15 min (data
not shown and Figure S6A). The low phosphorylation
levels seen after TGFα, AR, and EPI stimulation are not
because of limiting ligand concentration, since 10 times
higher ligand concentrations do not increase the Tyr1173
phosphorylation (data not shown and Figure S6B).
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Figure 5: EGFR binding of HB-EGF, BTC, and AR is acid-
resistant. HEp2 cells were incubated with 10 nM (EGF, TGF-α,
HB-EGF, and BTC) or 100 nM (AR) of unlabelled ligand on ice
for 6 h followed by a brief wash with buffers of various pH. The
number of ligand-free EGFRs was subsequently determined by
incubation with 125I-EGF for 1 h on ice. The graph shows the
relative increase in number of free binding sites following acid
wash at different pH. Data points represent mean +/− SEM for
three to six independent experiments.
To compare the site-speciﬁc phosphorylation pattern
to total phosphorylation of EGFR we incubated cells
with ligand on ice for 1 h followed by incubation at
37
◦C for 5 or 15 min (data not shown and Figure S6C),
and cell lysates were subjected to IP of EGFR. The
immunoprecipitates were analysed by western blotting
using EGFR antibodies and antibodies recognizing general
tyrosine phosphorylation. The pattern of site-speciﬁc
phosphorylation on EGFR is similar to that of total
phosphorylation, thus reﬂecting general activation.
Our data suggest that the levels of general tyrosine
phosphorylationandsite-speciﬁcphosphorylationof EGFR
after 5–20 min correlate well with the degree of EGFR
degradation following stimulation with the various ligands.
Discussion
Endocytic downregulation of EGFR is an important
process regulating EGFR signalling. In spite of this,
very little is known about how ligands other than EGF
and TGF-α affect EGFR internalization, recycling, and
degradation.We showherethatsixdifferent EGFRligands
differ substantially in their effects on EGFR trafﬁcking and
degradation (Figure 9).
An interesting question is whether EGFR trafﬁcking
following stimulation with the six different ligands occurs
as predicted by the current model of how this is regulated,
a model based solely on results of experiments with EGF
and TGF-α (5). Our data show that the behaviour of EPI
and BTC ﬁts well with the model for endocytic sorting of
EGFR. Accordingly, EPI stimulates endocytosis of EGFR
followed by complete recycling to the cell surface, and all
Figure 6: Differential effects of EGFR lig-
ands on EGFR ubiquitination and inter-
action with c-Cbl. A) HEp2 cells were
incubated 1 h on ice with 10 nM (EGF,
TGF-α, HB-EGF, and BTC) or 100 nM (AR
and EPI) ligand, washed, and incubated at
37
◦C for 5 min. Cells were lysed in RIPA
buffer, EGFR was immunoprecipitated and
the amount of EGFR ubiquitination deter-
mined by western blotting for ubiquitin. The
column bar graph shows the average inten-
sity of ubiquitin signal quantiﬁed from six to
seven independent experiments +/− SEM.
B–C): HEp2 cells were incubated 1 h on ice
with 10 nM (EGF, TGF-α, HB-EGF, and BTC)
or 100 nM (AR and EPI) ligand, washed, and
incubated at 37
◦C for 0–10 or 15 min (B
and C, respectively). Cells were lysed in co-
IP buffer; EGFR was immunoprecipitated;
and co-precipitation of c-Cbl or Grb2 was
determined by western blotting. The west-
ern blots shown are representative of three
to four independent experiments.
Trafﬁc 2009; 10: 1115–1127 1121Roepstorff et al.
Figure 7: Ubiquitination of EGFR is Cbl ubiquitin ligase-dependent for all ligands. HEp2 cells were transfected with scrambled
siRNA or c-Cbl and/or Cbl-b siRNA twice with 48 h interval. S = scrambled siRNA, C = c-Cbl siRNA, B = Cbl-b siRNA, and C + B =
c-Cbl and Cbl-b siRNA. A): 48 h after the last siRNA transfection, HEp2 cells were incubated for 1 h on ice with 10 nM (EGF, TGF-α,
HB-EGF, and BTC) or 100 nM (AR) ligand, washed, and incubated at 37
◦C for 15 min. Cells were lysed in RIPA buffer, EGFR was
immunoprecipitated, and the amount of EGFR ubiquitination determined by western blotting for ubiquitin. The column bar graph shows
the average intensity of ubiquitin signal quantiﬁed from three independent experiments +/− SEM. B): 48 h after last siRNA transfection,
HEp2 cells were lysed and the amounts of c-Cbl, Cbl-b, and transferrin receptor (TfR) were determined by western blotting. It is seen
that c-Cbl is knocked down after treatment with c-Cbl siRNA, but c-Cbl siRNA also has an effect on Cbl-b. Cbl-b siRNA is speciﬁc for
Cbl-b. TfR is used as a marker of protein levels.
of the parameters measured are in accordance with this
including low levels of EGFR Tyr1045 phosphorylation and
low levels of EGFR ubiquitination. BTC stimulates EGFR
degradation and in accordance with this, BTC leads to
EGFR Tyr1045 phosphorylation, persistent c-Cbl recruit-
ment, and EGFR ubiquitination. In contrast, the behaviour
of EGFR after stimulation with HB-EGF or AR cannot be
fully explained by the current model of EGFR sorting.
HB-EGF causes very efﬁcient EGFR Tyr1045 phosphory-
lation, abundant EGFR ubiquitination, and EGFR degra-
dation. However, there is only low and transitent c-Cbl
recruitmenttoEGFR following HB-EGFstimulation inspite
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Figure 8: Differential effects of EGFR
ligandsonTyr1173EGFRphosphoryla-
tion kinetics. HEp2 cells were incubated
1 h on ice with 10 nM (EGF, TGF-α,H B -
EGF, and BTC) or 100 nM (AR and EPI)
ligand, washed, and incubated at 37
◦Cf o r
0, 1.5, 5, 10 or 20 min. Cells were lysed
in RIPA buffer, and the amount of EGFR
phosphorylation determined by western
blotting for phosphorylation on Tyr1173.
TfR is used as a marker of protein levels.
The western blots shown are representa-
tive of three independent experiments.
of the heavy Tyr1045 phosphorylation. This is surprising,
since it is believed that phosphorylated Tyr1045 is an
important binding site for c-Cbl (27). Interestingly, c-Cbl
is recruited to EGFR in the early phases following HB-
EGF stimulation, and our c-Cbl knock down experiments
show that this ubiquitin ligase is necessary for full HB-EGF
induced EGFR ubiquitination. This shows the necessity of
testing receptor ubiquitination at a range of time-points,
including very early time-points.
AR stimulation for 5 min leads to profound EGFR
ubiquitination, but no receptor degradation. The lack of
degradation is most likely because of the fact that the
ubiquitination is rapidly lost, and therefore the receptor is
not targeted to lysosomal degradation, as has previously
been shown for TGF-α (7,28). In case of TGF-α,t h e
quick loss of ubiquitination is believed to be because
of the high pH sensitivity of this ligand (7,28). This is not
the case for AR, which is a highly acid-resistant ligand.
However, AR has a much lower afﬁnity for EGFR than
EGF, TGF-α, HB-EGF, and BTC. We therefore hypothesize
that the ligand is released from EGFR in endosomes
not because of pH sensitivity, but rather because of a
high off-rate causing the ligand to rapidly dissociate from
the receptor irrespective of the pH changes encountered
during trafﬁcking of EGFR.
Although the in vivo ligand concentrations have not
been determined for all of the investigated ligands, it
is conceivable that the concentrations used here are
physiologically and pathophysiologically relevant. In case
of EGF, concentrations vary strongly between different
body ﬂuids, reaching up to 8–80 nM in bile, urine,
milk and prostate ﬂuid (15,29–32). Normally, epithelia
prevent these ﬂuids from reaching EGFRs which are
expressed basolaterally, but when the tight junctions of
theepithelia becomeleaky,e.g.asa resultofpremalignant
Figure 9: Model for EGFR trafﬁcking after stimulation
with the six ligands. The model shows how EGFR is either
recycled or transported to lysosomes after stimulation with the
different ligands. See discussion for further details. PM, plasma
membrane.
neoplasia, high concentrations of EGF will reach and
activateEGFRs (33).Furthermore,elevatedlevelsofEGFR
ligand have been found in several cancer types (3,4,34).
Although an exact ligand concentration has not been
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measured in tumours, due to the auto- and paracrine
nature of the system, local EGFR ligand concentrations in
the tumour microenvironment may reach very high levels
as well.
The clinical signiﬁcance of over-expression of EGFR in a
multitude of cancers has been heavily investigated, and
many studies have reported that high expression of EGFR
in tumours is a marker of poor clinical outcome (2). Until
now, the expression levels of the EGFR ligands have
not been investigated to the same extent. Considering
their very diverse effects on the behaviour of EGFR, it is
of great importance to investigate which combinations
of EGFR ligands are expressed by a tumour (3). In
bladder cancer, HB-EGF, EPI, AR, and TGF-α have been
associated with a lower overall survival than has BTC
and EGF (4). Interestingly, apart from HB-EGF, the EGFR
ligands associated with poor survival are the ligands which
do not stimulate EGFR degradation and therefore allow
repeated activation of EGFR.
EGFR is a well-established drug target, with several
EGFR-targeting drugs on the market as well as in clinical
development. However, several studies have shown that
these drugs are effective on only a subset of cancer
patients. One of the most important challenges is to
identify the patients who will beneﬁt from EGFR-targeting
drugs prior to initiation of therapy. EGFR levels in the
tumour do not appear to correlate well with clinical
efﬁcacy (35,36). In this context, it will be of great interest
to investigate whether there is a correlation between
EGFR ligand expression proﬁle and sensitivity towards
EGFR-targeting drugs, and whether the potential of
the ligands to induce EGFR degradation correlates with
clinical efﬁcacy of EGFR-targeting drugs. In support of
this hypothesis, two recent studies showed that cancer
patients with tumours expressing either AR or EPI have a
better response to treatment with EGFR-targeting drugs
compared with patients with tumours not expressing AR
or EPI (37,38). Indeed, one may envision that tumours
relying heavily on EGFR signalling will tend to express
ligands that do not induce EGFR degradation, and that
these tumours therefore will be more sensitive to EGFR-
targeted treatment. This highlights the role of ligand-
induced EGFR degradation in limiting EGFR signalling, and
emphasizes the importance of expanding our knowledge
of how these processes are regulated.
Materials and Methods
Unless otherwise stated, reagents were purchased from Sigma-Aldrich.
Cell culture
HEp2 cells were maintained in DMEM supplemented with 10% FCS
(Biosera), 2 mM glutamax (Invitrogen), 1 mM sodium pyruvate, 200
U/mL penicillin, and 50 ng/mL streptomycin. Cells were serum-starved
in starvation medium (DMEM supplemented with 2 mM glutamax
(Invitrogen), 200 U/mL penicillin, and 50 ng/mL streptomycin) 4–18 h prior
to experiments.
EGFR internalization analysis
HEp2 cells were incubated on ice 1 h with the indicated concentration of
ligand (RnD Systems) in HEPES-buffered DMEM containing 0.2% BSA.
Cells were washed and incubated at 37◦C for the indicated period of
time with or without ligand in HEPES-buffered DMEM to allow receptor
internalization. Cells were subsequently placed on ice, washed 5 min with
an ice-cold acidic buffer (100 mM NaCl, 50 mM glycine, pH 2.5) to remove
any remaining bound ligand, neutralized with ice-cold PBS, and trypsinized
on ice until detachment of cells. Trypsin was neutralized by addition of soy
bean trypsin inhibitor, and the detached cells were ﬁxed 20 min in ice-cold
2% paraformaldehyde. The amount of EGFR present at the cell surface
was determinedby labellingof the unpermeabilizedﬁxed cells with an anti-
EGFR antibody(clone 199.12, Thermo Fisher Scientiﬁc) directly conjugated
to Alexa 488 (monoclonal antibody labelling kit, Invitrogen) followed by
FACS analysis to quantify EGFR surface labelling.
Determination of 125I-EGF binding kinetics on ice
HEp2 cells were incubated on ice with 125I-EGF (Perkin Elmer) for
0–60 min in HEPES-buffered DMEM containing 0.2% BSA. 125I-EGF was
removed and the cells were washed in ice-cold medium, hydrolysed in 0.5
M KOH, and the samples counted in a gamma-counter.
Determination of ligand-binding kinetics on ice
HEp2 cells were incubated on ice with unlabelled ligands for 0–120 min
in HEPES-buffered DMEM containing 0.2% BSA. Ligand was removed
and the cells were washed in ice-cold medium. To determine the number
of unoccupied EGFRs following ligand-binding, cells were subsequently
incubated with 125I-EGF for 30 min, washed, hydrolysed in 0.5 M KOH,
and the samples counted in a gamma-counter. Maximal 125I-EGF binding
was set to 0% and no 125I-EGF binding to 100%.
Immunoﬂuorescence staining and microscopy
HEp2 cells seeded in CC2-coated chamber slides were transfected with
peGFP-C3-Rab4a or peGFP-C2-Rab11a using FuGene6 (Roche) or left
untransfected. peGFP-C3-Rab4a and peGFP-C2-Rab11a were provided by
Marino Zerial (Max Planck Institute of Molecular Cell Biology and Genetics,
Dresden, Germany) and James R. Goldenring (Vanderbilt University,
Nashville, Tennessee), respectively. Two to three days after seeding,
cells were incubated with ligands in HEPES-buffered DMEM containing
0.2% BSA for 1 h on ice, rinsed in cold medium, and incubated for
0–120 min at 37◦C in warm medium with or without 500 nM baﬁlomycin
A1. Cells were rinsed in cold PBS and ﬁxed in 2% paraformaldehyde. After
ﬁxation,cellswerepermeabilizedandblockedinPBScontaining5%normal
goat serum (In Vitro) and 0.2% saponin. Immunoﬂuorescence labelling
was performed using the indicated combinations of primary antibodies
[mouse monoclonal anti-EGFR IgG2A antibody (clone 199.12, Thermo
Fisher Scientiﬁc), mouse monoclonal anti-EEA1 IgG1 antibody (clone 14,
BD Biosciences), mouse monoclonal anti-LAMP1 IgG1 antibody (clone
H4A3, Developmental Studies Hybridoma Bank)] and isotype speciﬁc
secondary antibodies (goat anti-mouse IgG, goat anti-mouse IgG1,a n d
goat anti-mouse IgG2A antibodies) conjugated to Alexa 488 or Alexa
568 (Invitrogen). Microscopy was done using a Zeiss LSM 510 Meta
confocal microscope, equipped with 488 and 543 nm excitation lasers,
using a 63 × 1.4 NA oil immersion apochromat objective. The pinhole
was set to allow acquisition of 1.0 or 1.4 μm thick confocal sections. For
each condition, images of a total number of approximately 50 cells were
acquired.
Image processing and quantitative analysis
Images were sectioned into smaller images containing a single cell each
using ImageJ with the MBF plug-in compilation. A binary mask deﬁning
the endosomes of the cells was made using Gaussian blur ﬁltering
(sigma = 1.0) of the EEA1 channel, and then 8-bit Otsu thresholding.
The density of the EGFR signal was then integrated for the endocytic
mask as well as for the entire cell. The relative amount of EGFR signal
contained within the endocytic mask was calculated by dividing the signal
from the mask with the total EGFR signal.
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EGFR degradation analysis using ELISA detection
HEp2 cells were incubated with ligands for 1 h on ice. After the pulse-
period, cells were rinsed in cold starvation medium and then incubated in
warm starvation medium containing 10 μg/mL cycloheximide at 37◦Cf o r
0–8 h. Cells were rinsed in cold PBS and scraped off in RIPA lysis buffer
(1% NP40, 20 mM MOPS, 0.1% SDS, 1% Na-deoxycholate, 150 mM
NaCl, and 1 mM ethylenediaminetetraacetic acid) supplemented with
Protease Inhibitor Cocktail Set II and Phosphatase Inhibitor Cocktail Set III
(Calbiochem). Cell debris was removed by spinning. EGFR content was
then measured using an EGFR ELISA kit (RnD Systems).
EGFR degradation analysis using 35S
methionine/cysteine labelling
Serum-starved cells were pre-incubated in methionine-/cysteine-free
DMEM supplemented with 1 mM sodium pyruvate, 2 mM glutamax, 200
U/mL penicillin, and 50 ng/mL streptomycin for 1 h. After preincubation,
cells were labelled with 0.25 mCi/mL L-[35S]-methionine/cysteine
(Mpbiomedicals) for 1–2 h. Cells were changed to starvation medium and
allowed to synthesize protein for 3 h. After 3 h cells were incubated with
ligands for 1 h on ice, then washed in starvation medium, and incubated
in starvation medium at 37◦C for 0–6 h. At the indicated times, cells were
rinsed in cold PBS and then scraped off in RIPA lysis buffer supplemented
with Protease Inhibitor Cocktail Set II and Phosphatase Inhibitor Cocktail
Set III. Cell debris was removed by spinning at 13,000 × g; the lysates
were pre-cleared with protein G Dynabeads (Invitrogen), and EGFR
immunoprecipitated with mouse monoclonal anti-EGFR antibody (clone
199.12) and protein G Dynabeads. The immunoprecipitates were resolved
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and EGFR
bands visualized by PhosphorImaging. The bands were quantiﬁed using
LabVision software (Thermo Fisher Scientiﬁc), and normalized to the sum
of signal detected in all EGFR-corresponding bands. The amount of EGFR
present right after removal of excess ligand, the 0 h control point, was set
to 100%. Whether the degradation after ligand stimulation is statistically
different from the 0 h control point was tested using Student’s t-test.
pH sensitivity of ligand-binding
HEp2 cells were incubated on ice 4 h, with the indicated concentration
of ligand in HEPES-buffered DMEM containing 0.2% BSA. Ligand was
removed and the cells were washed in ice-cold medium followed by
a 5-min wash with ice-cold buffers of varying pH (50 mM acetic acid,
50 mM HEPES, 50 mM NaCl, pH 2.5–7.5) followed by neutralization with
HEPES-buffered DMEM. To determine the number on unoccupied EGFRs
following the acid wash, cells were subsequently incubated with 125I-EGF
on ice for 1 h, washed, hydrolysed in 0.5 M KOH, and the samples counted
in a gamma-counter.
Cbl ubiquitin ligases knock down
HEp2 cells weretransfectedtwice with c-Cbl and/or Cbl-b siRNA (sc-29949
and sc-29950, Santa Cruz Biotechnology) or scrambled siRNA (AM4635,
Ambion) using Lipofectamine2000 (Invitrogen). Transfections were done
with 48 h interval and evaluation of EGFR ubiquitination and Cbl ubiquitin
ligases knock down was done 48 h after the second transfection. c-Cbl
and Cbl-b knock downs were evaluated with western blotting using a
rabbit polyclonal anti-c-Cbl antibody (sc-170, Santa Cruz Biotechnology), a
mouse monoclonal anti-Cbl-b antibody (G-1, Santa Cruz Biotechnology),
or a mouse monoclonal anti-transferrin antibody (H68.4, Zymed) and
horseradish peroxidase (HRP)-conjugated secondary antibodies.
Ubiquitination and total phosphorylation of EGFR
HEp2 cells were incubated on ice 1 h with the indicated concentration
of ligand in HEPES-buffered DMEM containing 0.2% BSA. Cells were
washed and incubated at 37◦C in HEPES-buffered DMEM for the indicated
periods of time, placed on ice and washed with ice-cold PBS before lysis
in RIPA buffer containing 10 nM n-ethylmaleimide, Benzonase (Novagen,
Merck Chemicals Ltd.), Protease Inhibitor Cocktail Set II, and Phosphatase
Inhibitor Cocktail Set III. Cell debris was removed by spinning, and EGFR
was immunoprecipitated from the lysate using a mouse monoclonal anti-
EGFR antibody (clone 199.12) and protein G sepharose beads or protein
G Dynabeads (Invitrogen). The precipitate was subject to western blotting
using a mouse monoclonal anti-ubiquitin antibody (clone P4D1, Santa
Cruz Biotechnology), a mouse monoclonal anti-tyrosine phosphorylation
antibody [clone 4G10, Upstate (Millipore)] or a sheep polyclonal anti-
EGFR antibody (Fitzgerald Antibodies) and HRP-conjugated secondary
antibodies (DAKO). Imaging and quantiﬁcation of bands were done using
ECL (Amersham Biosciences) and an AutoChemi system darkroom (UVP)
equipped with LabVision software (Thermo Fisher Scientiﬁc).
Co-immunopreciptation of EGFR and c-Cbl and Grb2
HEp2 cells were incubated on ice 1 h with the indicated concentration
of ligand in HEPES-buffered DMEM containing 0.2% BSA. Cells were
washed and incubated at 37◦C in HEPES-buffered DMEM for the indicated
periods of time, placed on ice and washed with ice-cold PBS before lysis
in co-IP buffer (0.5% Triton X-100, 50 mM KCl, 50 mM NaCl, 50 mM
Tris-HCl, pH 7.5,) containing 10 nM n-ethylmaleimide, Protease Inhibitor
Cocktail Set II, and Phosphatase Inhibitor Cocktail Set III. Cell debris was
removed by spinning at 13,000 × g, and EGFR was immunoprecipitated
from the lysate using a mouse monoclonal anti-EGFR antibody (clone
199.12, Thermo Fisher Scientiﬁc) and protein G dynabeads (Invitrogen).
The precipitate was subject to western blotting using a mouse monoclonal
anti-c-Cbl antibody (clone C-15, Santa Cruz Biotechnology), a rabbit anti-
Grb2 antibody (Cell Signaling Technology) or a sheep polyclonal anti-EGFR
antibody(FitzgeraldAntibodies)andHRP-conjugatedsecondaryantibodies.
Detection of Tyr1045, Tyr1068, Tyr1173
phosphorylation of EGFR
HEp2 cells were incubated on ice 1 h with the indicated concentration
of ligand in HEPES-buffered DMEM containing 0.2% BSA. Cells were
washed and incubated at 37◦C in HEPES-buffered DMEM for the indicated
periods of time, placed on ice and washed with ice-cold PBS before lysis in
RIPA buffer containing Protease Inhibitor Cocktail Set II and Phosphatase
InhibitorCocktailSetIII. Celldebriswas removedbyspinningat 13,000 × g
and lysates were subject to westernblottingusing mouse monoclonalanti-
transferrin antibody (H68.4, Zymed), mouse monoclonal phosphospeciﬁc
anti-EGFRpTyr1045 antibody (clone 11C2, NanoTools), mouse monoclonal
phosphospeciﬁc anti-EGFRpTyr1068 antibody (clone 15A2, NanoTools),
mouse monoclonal phosphospeciﬁc anti-EGFRpTyr1173 antibody [clone
9H2, Upstate (Millipore)] or a sheep polyclonal anti-EGFR antibody
(Fitzgerald Antibodies) and HRP-conjugated secondary antibodies.
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Figure S1:Ligands havereachedmaximalbinding to EGFR well before
1h . A): HEp2 cells were incubated on ice with 10 nM of EGF (1 nM 125I-
EGF and 9 nM unlabelled EGF) for 0–60 min and washed. Lysates were
counted in a gamma-counter. The graph shows the increase in bound
125I-EGF. Data points represent mean +/− SEM for ﬁve independent
experiments. B): HEp2 cells were incubated on ice with unlabelled ligands
for 0–120 min and washed. The number of unoccupied EGFRs following
the unlabelled ligand incubation was determined by incubation with 125I-
EGF. The graph shows the increase in unlabelled ligands bound. This
indirect method of measuring ligand-binding was used because some of
the EGFR ligands also bind to ErbB4, and it is therefore not possible to
separately analyse bindingto EGFR using directly labelled ligands. Maximal
125I-EGF binding was set to 0% and no 125I-EGF binding to 100%.
Figure S2: EGFR trafﬁcking after ligand stimulation is best monitored
by pulse-chase experiments. Time–course of EGFR internalization and
recycling following stimulation with EGF or TGF-α either as a pulse or
continuously. Cells were incubated on ice with 10 nM of ligands as
indicated, washed, and incubated at 37◦C for different time periods with
or without ligand in the medium. The amount of EGFR present at the cell
surface was determined by FACS analysis. Data points represent mean
+/− SEM for three independent experiments.
Figure S3: EGFR ligands differentially affect EGFR degradation. HEp2
cells were incubated on ice with 10 or 100 nM of ligands as indicated,
washed, and incubated at 37◦C for different time periods in the presence
of 10 μM cycloheximide to block protein synthesis. Cells were lysed, and
the amount of EGFR was determined by ELISA. Data points represent
mean +/− SEM for three to seven independent experiments.
Figure S4: EGFR localization to Rab-4 and Rab-11 positive endosomes
following AR stimulation. HEp2 cells were transfected with GFP-Rab-
4 or GFP-Rab-11, and incubated on ice with 100 nM AR, washed, and
incubated at 37◦C for 60 min. Cells were ﬁxed and labelled for EGFR.
Representative confocal microscopy images are shown. Bars, 10 μm.
Figure S5: Differential effects of EGFR ligands on EGFR ubiquitination
kinetics. HEp2 cells were incubated 1 h on ice with 10 nM (EGF, TGF-
α, HB-EGF, and BTC) or 100 nM (AR and EPI) ligand, washed, and
incubatedat 37◦Cfor0–20 min.CellswerelysedinRIPAbuffer,EGFRwas
immunoprecipitated, and the amount of EGFR ubiquitination determined
by western blotting for ubiquitin. Note that the overall intensity of the
different western blots should not be compared. To compare the effect
on ubiquitination levels between the different ligands, see Figure 6A. The
graphs show the average intensity of ubiquitin signal quantiﬁed from three
independent experiments +/− SEM.
Figure S6: Differential effects of EGFR ligands on EGFR phosphoryla-
tion. A) HEp2 cells were incubated for 1 h on ice with 10 nM (EGF, TGF-α,
HB-EGF, and BTC) or 100 nM (AR and EPI) ligand, washed, and incubated
at 37◦C for 15 min. Cells were lysed in RIPA buffer and the amount of
EGFR phosphorylation on Tyr1045, Tyr1068, and Tyr1173 was determined
by western blotting. The western blots shown are representative of four
independent experiments. B) HEp2 cells were incubated for 1 h on ice
with ligands in the following concentrations: 10 nM (EGF, TGF-α,H B - E G F ,
and BTC), 100 nM (AR and EPI), or the 10 times higher concentrations
for TGFα, AR, and EPI (100 nM TGFα, 1 μMA Ra n d1 μM EPI), Then cells
were washed, and incubated at 37◦C for 15 min. Cells were lysed in RIPA
buffer and the amount of EGFR phosphorylation on Tyr1173 was deter-
mined by western blotting. The western blots shown are representative
of three independent experiments. The column bar graph shows the aver-
age intensity of phosphorylation signal quantiﬁed from three independent
experiments +/− SEM. C): HEp2 cells were incubated for 1 h on ice with
10 nM (EGF, TGF-α, HB-EGF, and BTC) or 100 nM (AR and EPI) ligand,
washed, and incubated at 37◦C for 15 min. Cells were lysed in RIPA buffer,
EGFR was immunoprecipitated, and the amount of EGFR ubiquitination
determined by western blotting for phosphorylated tyrosine. The column
bar graph shows the average intensity of phosphorylation signal quantiﬁed
from four independent experiments +/− SEM.
Please note: Wiley-Blackwell are not responsible for the content or
functionality of any supporting materials supplied by the authors.
Any queries (other than missing material) should be directed to the
corresponding author for the article.
References
1. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp.Cell Res
2003;284:2–13.
2. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De LA,
Caponigro F, Salomon DS. The ErbB receptors and their ligands in
cancer: an overview. Curr.Drug Targets 2005;6:243–257.
3. Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. ErbB/HER
ligands in human breast cancer, and relationships with their
receptors, the bio-pathological features and prognosis. Ann Oncol
2008;19:73–80.
4. Thogersen VB,Sorensen BS,Poulsen SS,Orntoft TF,Wolf H,Nexo E.
A subclass of HER1 ligands are prognostic markers for survival in
bladder cancer patients. Cancer Res 2001;61:6227–6233.
5. Roepstorff K, Grøvdal LM, Grandal M, Lerdrup M, van Deurs B.
Endocytic downregulation of ErbB receptors: mechanisms and
relevance in cancer. Histochem.Cell Biol 2008;129:563–578.
6. Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, Reddi AL,
Ghosh A, Fernandes N, Zhou P, Mullane-Robinson K, Rao N,
Donoghue S, Rogers RA, Bowtell D, Naramura M et al. Cbl-mediated
ubiquitylation is required for lysosomal sorting of epidermal growth
factor receptor but is dispensable for endocytosis. J Biol Chem
2003;278:28950–28960.
7. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Mad-
shus IH. Ubiquitination and proteasomal activity is required for trans-
port of the EGF receptor to inner membranes of multivesicular bodies.
J Cell Biol 2002;156:843–854.
8. Raiborg C, Rusten TE, Stenmark H. Protein sorting into multivesicular
endosomes. Curr Opin Cell Biol 2003;15:446–455.
9. Ebner R,Derynck R.Epidermalgrowthfactorandtransforminggrowth
factor-alpha: differential intracellular routing and processing of ligand-
receptor complexes. Cell Regul 1991;2:599–612.
10. Decker SJ. Epidermal growth factor and transforming growth factor-
alpha induce differential processing of the epidermal growth factor
receptor. Biochem Biophys Res Commun 1990;166:615–621.
11. Waterman H, Sabanai I, Geiger B, Yarden Y. Alternative intracellular
routing of ErbB receptors may determine signaling potency. J Biol
Chem 1998;273:13819–13827.
12. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the
ErbB/epidermal growth factor (EGF) receptor family and its ligands in
ovarian cancer. Biochim Biophys Acta 2008;1785:232–265.
13. Torring N, Jorgensen PE, Sorensen BS, Nexo E. Increasedexpression
of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and
epiregulin in androgen-independent prostate cancer cell lines.
Anticancer Res 2000;20:91–95.
14. Sorkin A, Krolenko S, Kudrjavtceva N, Lazebnik J, Teslenko L,
Soderquist AM, Nikolsky N. Recycling of epidermal growth factor-
receptor complexes in A431 cells: identiﬁcation of dual pathways.
J Cell Biol 1991;112:55–63.
15. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP.
Clathrin-mediated internalization is essential for sustained EGFR
signaling but dispensable for degradation. Dev Cell 2008;15:209–219.
16. Jones JT, Akita RW, Sliwkowski MX. Binding speciﬁcities and afﬁni-
ties of egf domains for ErbB receptors. FEBS Lett 1999;447:227–231.
1126 Trafﬁc 2009; 10: 1115–1127EGFR Ligands
17. Shoyab M, Plowman GD, McDonald VL, Bradley JG, Todaro GJ.
Structure and function of human amphiregulin: a member of the
epidermal growth factor family. Science 1989;243:1074–1076.
18. Oksvold MP, Skarpen E, Lindeman B, Roos N, Huitfeldt HS. Immuno-
cytochemical localization of Shc and activated EGF receptor in
early endosomes after EGF stimulation of HeLa cells. J Histochem
Cytochem 2000;48:21–33.
19. Zerial M, McBride H. Rab proteins as membrane organizers. Nat Rev
Mol Cell Biol 2001;2:107–117.
20. Baldys A, Gooz M, Morinelli TA, Lee MH, Raymond JR, Jr., Luttrell
LM, Raymond JR, Sr. Essential role of c-Cbl in amphiregulin-induced
recycling and signaling of the endogenous epidermal growth factor
receptor. Biochemistry 2009;48:1462–1473.
21. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY,
Beguinot L, Geiger B, Yarden Y. c-Cbl/Sli-1 regulatesendocyticsorting
and ubiquitinationof the epidermal growth factor receptor. Genes Dev
1998;12:3663–3674.
22. Jiang X, Huang F, Marusyk A, Sorkin A. Grb2 regulates internalization
of EGF receptors through clathrin-coated pits. Mol Biol Cell
2003;14:858–870.
23. Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A, Jovin T,
Yarden Y. A mutant EGF-receptor defective in ubiquitylation and
endocytosis unveils a role for Grb2 in negative signaling. EMBO J
2002;21:303–313.
24. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY,
Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y.
Ubiquitin ligase activity and tyrosine phosphorylation underlie
suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell
1999;4:1029–1040.
25. Huang F, Sorkin A. Growth factor receptor binding protein 2-mediated
recruitment of the RING domain of Cbl to the epidermal growth factor
receptor is essential and sufﬁcient to support receptor endocytosis.
Mol Biol Cell 2005;16:1268–1281.
26. Ettenberg SA,Keane MM,Nau MM,Frankel M,Wang LM,Pierce JH,
Lipkowitz S. cbl-b inhibits epidermal growth factor receptor signaling.
Oncogene 1999;18:1855–1866.
27. Grøvdal LM, Stang E, Sorkin A, Madshus IH. Direct interaction of
Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort
the EGFR to lysosomes for degradation. Exp Cell Res
2004;300:388–395.
28. Alwan HA,vanZoelen EJ,vanLeeuwen JE.Ligand-inducedlysosomal
epidermal growth factor receptor (EGFR) degradation is preceded
by proteasome-dependent EGFR de-ubiquitination. J Biol Chem
2003;278:35781–35790.
29. Hayashi T, Sakamoto S. Radioimmunoassay of human epidermal
growth factor–hEGF levels in human body ﬂuids. J Pharmacobiodyn
1988;11:146–151.
30. Grau M, Rodriguez C, Soley M, Ramirez I. Relationship between
epidermal growth factor in mouse submandibular glands, plasma,
and bile: effects of catecholamines and fasting. Endocrinology
1994;135:1854–1862.
31. Beardmore JM,Richards RC.Concentrationsofepidermalgrowthfac-
torinmousemilkthroughoutlactation.JEndocrinol1983;96:287–292.
32. Gann PH, Chatterton R, Vogelsong K, Grayhack JT, Lee C. Epidermal
growth factor-related peptides in human prostatic ﬂuid: sources of
variability in assay results. Prostate 1997;32:234–240.
33. Mullin JM. Epithelial barriers, compartmentation, and cancer.
Sci.STKE 2004;2004:e2.
34. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De LA,
Caponigro F, Salomon DS. The ErbB receptors and their ligands in
cancer: an overview. Curr Drug Targets 2005;6:243–257.
35. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A,
Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van CE.
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-
refractory metastatic colorectal cancer. N Engl J Med 2004;351:
337–345.
36. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ.
Phase II trial of cetuximab in patients with refractory colorectal cancer
that expresses the epidermal growth factor receptor. J Clin Oncol
2004;22:1201–1208.
37. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT,
Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krish-
namurthi SS, Burris HA, III, Poplin EA, Hidalgo M et al. Expression of
epiregulin and amphiregulin and K-ras mutation status predict dis-
ease control in metastatic colorectal cancer patients treated with
cetuximab. J Clin Oncol 2007;25:3230–3237.
38. Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM,
Zhao F, Rogers AM, Johnson BE, Janne PA. Autocrine production of
amphiregulin predicts sensitivity to both geﬁtinib and cetuximab in
EGFR wild-type cancers. Clin Cancer Res 2008;14:6963–6973.
Trafﬁc 2009; 10: 1115–1127 1127